Unlike the characteristic molecules that are relatively easy to target in hematologic tumors (e.g., CD19, CD20, BCMA, etc.), in the vast majority of autoimmune diseases, the specific autoantibody-mediated antigenic targets are still unknown. This evidence concerns the gene CD19 and autoimmune disease.